Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7aaab35abccf4a7bff9f7f3fdd70807f |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61F2013-0296 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P23-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-7053 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-7061 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-7084 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-703 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-445 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4535 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-445 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-70 |
filingDate |
2005-10-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate |
2010-10-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f3287f5e01055de51569d0910d8ce9db http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_08da9a12d56f85a5462b840e4a36f4b2 |
publicationDate |
2010-10-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
ES-2346895-T3 |
titleOfInvention |
TRANSDERMAL ADMINISTRATION SYSTEMS. |
abstract |
A transdermal delivery system for administering sufentanil through the skin of a living subject, said system comprising a pressure sensitive adhesive matrix comprising: # - sufentanil; and # - a mixture of: (i) a high molecular weight polyisobutylene having an average molecular weight in viscosity of 450,000 to 2,100,000; and (ii) a low molecular weight polyisobutylene having an average molecular weight in viscosity of 1,000 to 450,000; # in which said system provides a substantially constant rate of administration of sufentanil during a single application administration period of at least about 48 hours and said constant administration rate is sufficient to establish and maintain a plasma sufentanil concentration having a minimum to maximum ratio of approximately 1.8 or less during said administration period. |
priorityDate |
2004-10-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |